US Stock MarketDetailed Quotes
VALN Valneva
- 7.925
- -0.205-2.52%
Trading Apr 19 11:44 ET
551.39MMarket Cap-5099P/E (TTM)
7.970High7.810Low7.98KVolume7.870Open8.130Pre Close62.93KTurnover0.02%Turnover RatioLossP/E (Static)69.58MShares17.05052wk High4.04P/B391.18MFloat Cap6.58052wk Low--Dividend TTM49.36MShs Float67.840Historical High--Div YieldTTM1.97%Amplitude6.580Historical Low7.889Avg Price1Lot Size
Valneva Stock Forum
Sign in to post a comment
Biotech Stock News 3/20
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
Valneva predicts a lower cash burn this year than in 2023, with its commercial business expected to be cash-flow positive and significantly fund the company's R&D from 2025. The company also foresees lower R&D expenses, narrowing guidance to €60 million to €75 million.
1
Valneva's new governance structure is expected to improve the company's leadership effectiveness and efficiency according to CEO Thomas Lingelbach, while Anne-Marie Graffin expresses her commitment to deliver on the company's ambition and growth trajectory in the interest of all stakeholders.
CEO Thomas Lingelbach sees industry-standard governance as a boost for Valneva's leadership efficacy and efficiency. Departing chairman Frederic Grimaud has faith in the organization's chikungunya and Lyme disease ventures progress.
COVID-19 vaccine makers fall as Biden says pandemic is over
Leading COVID-19 vaccine developers continued to decline towards Monday's close after President Joe Biden said that the pandemic is a thing of the past despite ongoing concerns related to the virus.
"The pandemic is over," he said Sunday during a 60 Minutes interview on the sidelines of the Detroit auto show, adding, "We still have a problem with COVID. We're still doing a lot of work on it. But the pandemic is over."
Shortly after 3:30P...
"The pandemic is over," he said Sunday during a 60 Minutes interview on the sidelines of the Detroit auto show, adding, "We still have a problem with COVID. We're still doing a lot of work on it. But the pandemic is over."
Shortly after 3:30P...
9
2
$Valneva(VALN.US$ bleeding
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
diamonds : 请问，ENDPQ重组后，持有的股票还能有效吗？